Also known as: IRF8 Gene Sequencing, Immunodeficiency Type 32A Genetic Test, Mycobacteriosis Susceptibility Test
Test Price
2,800 AEDโ Home Collection Available
๐ Results in 3โ4 Weeks
IRF8 Gene Immunodeficiency Type 32A, Mycobacteriosis, Autosomal Dominant Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- โ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
- โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- โ Clinical Guidance: Complimentary Telephonic Post-Test Genetic Counselling with DHA-Licensed Geneticist.
- โ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
This comprehensive test detects autosomal dominant mutations in the IRF8 gene, which cause immunodeficiency type 32A and severe susceptibility to mycobacterial infections. The analysis is performed using Illumina Next-Generation Sequencing with 500x depth, ensuring high diagnostic yield. All processes comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The IRF8 genetic test uses advanced Next-Generation Sequencing (NGS) to analyze the entire coding region and splice sites of the IRF8 gene. This methodology identifies pathogenic autosomal dominant variants associated with immunodeficiency type 32A and increased risk of mycobacterial disease. The test is performed in our DHA-licensed laboratory using validated protocols.
| Feature | Our NGS Test (DHA-Certified) | Closest Alternative (Sanger/Chip) |
|---|---|---|
| Technology | Illumina NGS with 500x depth | Sanger sequencing / targeted arrays |
| Diagnostic Sensitivity | 99.9% (ISO 9001 validated) | 85โ92% |
| Turnaround Time | 3โ4 Weeks | 6โ8 Weeks |
| LIMS Integration | Full EMR/DHA MOHAP compatible | Limited |
Physician Insight & Safety Protocols
"As a DHA-licensed Consultant Medical Genetics, I emphasize that interpretation of this IRF8 gene analysis must be integrated with the patient's complete medical history, family pedigree, and immunological workup. A positive result does not automatically dictate treatment decisions โ careful clinical correlation and a dedicated post-test genetic counselling session are essential to guide management. Never discontinue or modify prescribed immunosuppressive or antimicrobial therapy without consulting the treating physician."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory โ Medication Safety
โ Do not discontinue any prescribed medication without consulting your doctor. Genetic results require professional clinical correlation.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Active life-threatening infection requiring ICU admission; severe bleeding disorder if blood draw is planned (use non-invasive FTA card alternative).
- Exclusion: Patient inability to provide informed consent (minors require guardian consent per Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Red Flag: New-onset high fever, suppurative lymphadenitis, or disseminated skin lesions โ seek immediate ER evaluation before testing.
- Red Flag: Signs of meningitis or acute respiratory distress; this test is not a substitute for urgent infectious disease management.
Patient FAQ & Clinical Guidance
1. What does the IRF8 genetic test detect, and why is it critical?
Snippet: It identifies autosomal dominant mutations in the IRF8 gene causing immunodeficiency type 32A and life-threatening mycobacterial susceptibility. Early diagnosis enables targeted prophylaxis and management.
2. How is the sample collected, and is home collection available across the UAE?
Snippet: We offer a painless blood draw or a simple blood spot on an FTA card. Our DHA-licensed mobile phlebotomists provide home collection in 60-minute slots across Dubai, Abu Dhabi, and all Emirates.
3. When will I receive results, and what does a positive report mean?
Snippet: Results are delivered in 3โ4 weeks with a DHA-validated clinical report flagging pathogenic variants and management recommendations. A positive result indicates a hereditary predisposition that should be discussed with a geneticist and immunologist.
UAE Regulatory & Data Privacy Adherence
Data Protection & Healthcare Compliance
All genetic data and personal health information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our laboratory holds DHA Facility License No. 1143 and ISO 9001:2015 certification.
Clinical & Logistical Metadata
| Test Name | IRF8 Gene Sequencing (Immunodeficiency Type 32A, Autosomal Dominant, Mycobacteriosis Susceptibility) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (Illumina, 500x coverage, full gene analysis) |
| ICD-10-CM Code | D84.8 (Other specified immunodeficiencies) |
| LOINC Code | 21639-0 (Genetic analysis, DNA, gene mutation analysis) |
| DHA Facility License & Lab Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
["No specific fasting required", "Inform lab of any current medications"]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians